Hemera is pleased to announce the appointment of Michela Pantaleoni to its Board of Directors. Michela brings over twenty years of experience in the Life Sciences sector, with deep expertise in the launch and market access of innovative therapies, particularly in areas of high unmet medical need and rare diseases.
In her role, Michela will support Hemera in the development of pricing and market access strategies and in the value creation of its innovative assets, contributing to the company’s continued growth in the biotechnology and regenerative medicine fields.
Her global experience at companies such as AstraZeneca, Chiesi Global Rare Diseases, and Napo Therapeutics, together with her commitment to inclusive innovation and female entrepreneurship, strengthens the Board with strategic insight and a pragmatic approach to engagement with regulatory bodies and key stakeholders.
Welcome to Michela, from all of us at Hemera!